DMNeuro Australia validation study begins

Australian Validation Study Begins for DMNeuro Novavica is proud to announce the commencement of our Australian validation study for DMNeuro in partnership with leading research institutions. This landmark study will systematically evaluate the effects of the Super Formula on cognitive function in early-stage cognitive decline. The study will utilize standardized cognitive assessment tools to measure outcomes, while also incorporating quality-of-life metrics to understand the holistic impact on patients and caregivers. “This represents a significant step in our mission to bridge Eastern and Western approaches to cognitive health,” said Dr. James Wilson, Scientific Director at Novavica. “By applying rigorous scientific methodologies to evaluate traditional formulas, we can potentially accelerate access to effective solutions.” The study will involve 120 participants across multiple sites in Australia, with results expected within 18 months. Novavica has developed the protocol in consultation with the Australian Dementia Network (ADNeT) to ensure alignment with best practices in dementia research. [Additional image of research team meeting] Participants will be monitored for cognitive performance, brain health biomarkers, and quality of life measures. The study design includes appropriate controls and blinding procedures to ensure scientific validity. We look forward to sharing updates as this important research progresses.